期刊文献+

P2Y_(12)受体拮抗剂最新研究进展 被引量:3

原文传递
导出
摘要 心脑血管疾病业已成为我国居民死亡的首要原因,据统计,在我国至少有2.3亿心血管病患者,因心血管病的死亡约占总死亡的1/3[1].近些年来,栓塞性的心脑血管疾病发病率呈明显上升趋势.血小板的聚集、活化和释放在血栓的形成的关键环节.因此,抗血小板治疗在防治血栓形成中具有重要意义.本文主要针对新型抗血小板药P2Y12受体拮抗剂的研究进展进行综述.
出处 《中华临床医师杂志(电子版)》 CAS 2012年第19期6001-6003,共3页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献10

  • 1Siller-Matula JM;Krumphuber J;Jilma B.Pharmacokinetic,pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases,2010.
  • 2O′Donoghue ML;Braunwald E;Antman EM.Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor:an analysis of two randomised trials,2009.
  • 3Bouman HJ;van Werkum JW;Hackeng CM.Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects,2009.
  • 4Kastrati A;Ndrepepa G.Cangrelor-champion lost in translation,2009.
  • 5Harrington RA;Stone GW;McNulty S.Platelet inhibition with cangrelor in patients undergoing PCI,2009.
  • 6Nguyen TA;Diodati JG;Pharand C.Resistance to clopidogrel:A review of the evidence,2005.
  • 7Gurbel PA;Bliden KP;Butler K.Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease(The ONSET/OFFSET Study),2009.
  • 8胡盛寿;孔灵芝.中国心血管病报告2008-2009.
  • 9Das P;Oliphant CS;Beach E.Emerging antiplatelet agents,differential pharmacology,and clinical utility,2010(01).
  • 10Dovlatova NL;Jakubowski JA;Sugidachi A.The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function,2008.

同被引文献35

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部